AU2018100388A4 - Medicine intermediates sulfanilic acid synthesis method - Google Patents
Medicine intermediates sulfanilic acid synthesis method Download PDFInfo
- Publication number
- AU2018100388A4 AU2018100388A4 AU2018100388A AU2018100388A AU2018100388A4 AU 2018100388 A4 AU2018100388 A4 AU 2018100388A4 AU 2018100388 A AU2018100388 A AU 2018100388A AU 2018100388 A AU2018100388 A AU 2018100388A AU 2018100388 A4 AU2018100388 A4 AU 2018100388A4
- Authority
- AU
- Australia
- Prior art keywords
- solution
- temperature
- sulfanilic acid
- synthesis method
- mass fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Abstract Medicine intermediates sulfanilic acid synthesis method, comprises the following steps: 3mol 4-aminophenol, 4-5mol 2-sulfonic acid toluene and 10-16g aluminum 5 chloride powder are added to the reaction vessel, and the temperature of the solution is raised to 90-110 0C, after the addition is complete, and the temperature is kept for 80-120min, reduce the solution temperature to 10-15 C, adding 2L potassium bromide solution, crystals precipitated, filter it, the crystal dissolved in potassium carbonate solution, reduce the solution temperature to 5-8 C, crystals precipitated, filter out the 10 crystal, washed with bromine chloride solution, and with triethylamine solution, and with nitromethane solution, dehydrated with dehydrating agent, drying at 110-115 'C, finally get product sulfanilic acid.
Description
FIELD OF THE INVENTION
The present invention relates to medicine intermediates sulfanilic acid synthesis 5 method.
GENERAL BACKGROUND
Sulfanilic acid is mainly used for organic synthesis of pharmaceuticals, brighteners, pesticides and other intermediates, however, most of the existing synthetic methods are complicated and the final yield is not very high. Therefore, it is necessary to propose a new synthetic method for further improving the quality and yield of the product and reducing the byproduct content, it has important economic significance.
SUMMARY
The purpose of the present invention is to provide medicine intermediates sulfanilic acid synthesis method, comprises the following steps:
(i) 3mol 4-aminophenol, 4-5mol 2-sulfonic acid toluene and 10-16g aluminum chloride powder are added to the reaction vessel, and the temperature of the solution is raised to 90-110°C, after the addition is complete, and the temperature is kept for
80-120min , reduce the solution temperature to 10-15 °C, adding 2L potassium bromide solution, crystals precipitated, filter it, the crystal dissolved in potassium carbonate solution, reduce the solution temperature to 5-8°C, crystals precipitated, filter out the crystal, washed with bromine chloride solution, and with triethylamine solution, and with nitro methane solution, dehydrated with dehydrating agent, drying at 110-115 °C, finally get product sulfanilic acid; wherein, the mass fraction of potassium carbonate solution in the step (i) is 30-36%, the mass fraction of the potassium bromide solution in the step (i) is 10-17%, the mass fraction of the triethylamine solution in the step (i) is 50-55%, the mass of the nitro methane solution in the step (i) is 65-70%, the dehydrating agent in step (i) is any one of solid sodium hydroxide and anhydrous magnesium sulfate.
2018100388 28 Mar 2018
Throughout the reaction process can be the following reaction formula:
ch3
Advantage of the present invention is that: reducing intermediate links reaction, decreasing the reaction time and improving the reaction yield.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The following examples with reference to specific embodiments of the present invention arc further illustrated:
medicine intermediates sulfanilie acid synthesis method.
Embodiment 1 mol 4-aminophenol, 4 mol 2-sulfotoluene and 10 g aluminum chloride powder were added to the reaction vessel, after the addition, the temperature of the solution was increased to 90°C and kept for 80 min. lowering the solution temperature to 10°C, adding 2L potassium bromide solution with a mass fraction of 10%, crystals precipitated, filter it, the crystal was dissolved in 30% potassium carbonate solution, the temperature of the solution was reduced to 5C, the crystal was separated out, and the crystal was filtered out, washed with potassium bromide solution with a mass fraction of 10%, and washed with the triethylamine solution with a mass fraction of
50%, washed with the nitro methane solution with a mass fraction of 65%, dehydrated with solid sodium hydroxide dehydration, drying at 1 LO°C, finally get product sulfanilie acid 461,91 g, yield 89%.
Embodiment 2
3 mol 4-aminophcnol, 4.5 mol 2-sulfonic acid toluene and 13 g aluminum chloride powder were added to the reaction vessel, after the addition, the temperature of the solution was raised to 100 °C and kept for 100 min, lowering the solution temperature
2018100388 28 Mar 2018 to 12°C, adding 2L potassium bromide solution with a mass fraction of 13%, crystals precipitated, filter it, the crystal was dissolved in 33% potassium carbonate solution, and the temperature of the solution was reduced to 6 °C, the crystal was precipitated and the crystal was filtered out, washed with potassium bromide solution with a mass fraction of 13%, and with triethylamine solution the mass fraction of 52%, and with nitromethane solution with a mass fraction of 67%, dehydrated with anhydrous magnesium sulfate dehydration, drying at 112 °C, finally get product sulfanilic acid 477.48 g, yield 92%.
Embodiments mol 4-aminophenol, 5 mol 2-sulfonic acid toluene and 16 g aluminum chloride powder were added to the reaction vessel, after the addition, the temperature of the solution was increased to 110 °C and kept for 120 min, reduced the solution temperature to 15 °C, adding 2L potassium bromide solution with a mass fraction of
17%, crystals precipitated, filter it, the crystal was dissolved in 36% potassium carbonate solution and the temperature of the solution was reduced to 8 °C, the crystal was precipitated and the crystal was filtered out, washed with potassium bromide solution with a mass fraction of 17%, and with triethylamine solution with a mass fraction of 55%, washed with nitromethane solution with a mass fraction of 70%, dehydrated with solid sodium hydroxide dehydration, drying at 115°C, finally get product sulfanilic acid 487.86 g, yield 94%.
2018100388 28 Mar 2018
Claims (2)
- Claims1. Medicine intermediates sulfanilic acid synthesis method, comprises the following steps:(i) 3mol 4-aminophenol, 4-5mol 2-sulfonic acid toluene and 10-16g aluminum 5 chloride powder are added to the reaction vessel, and the temperature of the solution is raised to 90-110°C, after the addition is complete, and the temperature is kept for 80-120min , reduce the solution temperature to 10-15 °C, adding 2L potassium bromide solution, crystals precipitated, filter it, the crystal dissolved in potassium carbonate solution, reduce the solution temperature to 5-8°C, crystals precipitated,10 filter out the crystal, washed with bromine chloride solution, and with triethylamine solution, and with nitromethane solution, dehydrated with dehydrating agent, drying at 110-115 °C, finally get product sulfanilic acid; wherein, the mass fraction of potassium carbonate solution in the step (i) is 30-36%, the mass fraction of the potassium bromide solution in the step (i) is 10-17%, the mass fraction of the15 triethylamine solution in the step (i) is 50-55%.
- 2. Medicine intermediates sulfanilic acid synthesis method according to claim 1 wherein the mass of the nitro methane solution in the step (i) is 65-70%.20 3. Medicine intermediates sulfanilic acid synthesis method according to claim 1 wherein the dehydrating agent in step (i) is any one of solid sodium hydroxide and anhydrous magnesium sulfate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710070377.8A CN108409610A (en) | 2017-02-09 | 2017-02-09 | A kind of synthetic method of medicine intermediate p-aminobenzene sulfonic acid |
| GBGB1705480.0A GB201705480D0 (en) | 2017-02-09 | 2017-04-05 | Medicine intermediates sulfanilic acid synthesis method |
| GBGB1705480.0 | 2017-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018100388A4 true AU2018100388A4 (en) | 2018-05-10 |
Family
ID=58682716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018100388A Ceased AU2018100388A4 (en) | 2017-02-09 | 2018-03-28 | Medicine intermediates sulfanilic acid synthesis method |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN108409610A (en) |
| AU (1) | AU2018100388A4 (en) |
| GB (1) | GB201705480D0 (en) |
-
2017
- 2017-02-09 CN CN201710070377.8A patent/CN108409610A/en active Pending
- 2017-04-05 GB GBGB1705480.0A patent/GB201705480D0/en not_active Ceased
-
2018
- 2018-03-28 AU AU2018100388A patent/AU2018100388A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB201705480D0 (en) | 2017-05-17 |
| CN108409610A (en) | 2018-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Palladium-catalyzed aerobic oxidative coupling of enantioenriched primary allylic amines with sulfonyl hydrazides leading to optically active allylic sulfones | |
| CN103333111A (en) | Preparation method of lorcaserin hydrochloride | |
| AU2018100388A4 (en) | Medicine intermediates sulfanilic acid synthesis method | |
| IES86997B2 (en) | Medicine intermediates sulfanilic acid synthesis method | |
| AU2018100389A4 (en) | Drugs intermediates m-aminobenzoic acid synthesis method | |
| AU2018100387A4 (en) | Organic synthesis intermediates m-aminobenzenesulfonic acid synthesis method | |
| AU2018100363A4 (en) | Drug intermediates aluminium isopropoxide synthesis method | |
| AU2018100415A4 (en) | Drugs intermediates 1,4-dibromo-2,3-butanediol synthesis method | |
| AU2018100420A4 (en) | Organic synthesis raw materials valeric acid synthesis method | |
| AU2018100365A4 (en) | Antagonists medicine intermediates o-nitrobenzoic acid synthesis method | |
| AU2018100367A4 (en) | Fluconazole drugs intermediates 2,4-dinitrobenzoic acid synthesis method | |
| AU2018100386A4 (en) | Drug intermediates o-aminobenzaldehyde synthesis method | |
| AU2018100423A4 (en) | Drugs intermediates 2,5-dichlorobenzoic acid synthesis method | |
| IES86998B2 (en) | Drugs intermediates m-amionbenzoic acid synthesis method | |
| WO2015193911A1 (en) | Process for the preparation of 2-(trihalomethyl) benzamide | |
| AU2016102241A4 (en) | Calcipotriene acid drug intermediates ε- (3,4,5- trimethoxybenzoyl amino) - acetic acid synthesis method | |
| AU2018100396A4 (en) | Medicine intermediates 2,4-difluorobenzoic acid synthesis method | |
| AU2018100362A4 (en) | Organic synthesis intermediates N-propenyl urea synthesis method | |
| AU2016102242A4 (en) | Busulfan drug intermediates 1, 4 - methyl sulfonic acid butyl ester synthesis method | |
| IES86950B2 (en) | Drug intermediates o-aminobenzaldehyde synthesis method | |
| IES86999B2 (en) | Drugs intermediates o-aminobenzoic acid synthesis method | |
| AU2018100395A4 (en) | Drug intermediates parachlorobenzoic-acid synthesis method | |
| AU2018100417A4 (en) | Raw materials of organic synthesis tridecanoic acid synthesis method | |
| CN112209838B (en) | Preparation method of butenaphthol hydrochloride | |
| AU2018101117A4 (en) | Drug intermediates 3-oxoheptanone ethylene glycol synthesis method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |